



Abbreviations and acronyms

3TC	Lamivudine	CNS	Central Nervous System
ANDA	Abbreviated New Drug Application	CONRAD	Contraceptive Research and Development Program
API	Active Pharmaceutical Ingredient	CRL	Complete Response Letter
ART	Antiretroviral Therapy	CROI	Conference on Retroviruses and Opportunistic Infections
ARV	Antiretroviral	CVD	Cardiovascular Disease
AS/AQ	Artesunate/Amodiaquine	DAC	Daclatasvir
ASO	Antisense Oligonucleotide	DALYs	Disability-Adjusted Life Years
BCS	Biopharmaceutical Classification System	DDI	Drug-Drug Interactions
BE	Bioequivalence	DOR	Doravirine
BIC	Bictegravir	DOT	Directly Observed Therapy
BMI	Body Mass Index	DPP4i	Dipeptidyl Peptidase IV Inhibitors
bNAbs	Broadly Neutralising Antibodies	DrpE1	Decaprenylphosphoryl- β -d-ribose-2'-epimerase
BRAF	v-Raf Murine Sarcoma Viral Oncogene Homolog B1	DTG	Dolutegravir
BTKi	Bruton's Tyrosine Kinase Inhibitor	DZIF	German Center for Infection Research
°C	Degree Celsius	EGFR	Epidermal Growth Factor Receptor
CAB	Cabotegravir	EGFR TKI	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
CAB-LA	Cabotegravir Long-Acting	EGFRm	Epidermal Growth Factor Receptor mutation
CAB-ULA	Cabotegravir Ultra Long-Acting	EMA	European Medicines Agency
CADO	Community Advisory Panel	EML	Essential Medicines List
CAP	Community Advisory Panel	EML	Essential Medicines List
CDK 4/6	Cyclin-Dependent Kinase 4 and 6	EPFL	École Polytechnique Fédérale de Lausanne
CF	Cystic Fibrosis	Eto	Ethionamide
CFTR	Cystic Fibrosis Transmembrane Conductance Regulator	EU MAA	European Marketing Authorisation
CKD	Chronic Kidney Disease	EU-M4all	EU-Medicines for all (Scientific opinions by EMA & WHO for markets outside the EU)
CLL	Chronic Lymphocytic Leukemia	EVG	Elvitegravir



FTC	Emtricitabine
FTC	Emtricitabine
GAP-f	Global Accelerator for Paediatric Formulations
GIP	Gastric inhibitory polypeptide
GLP-1	Glucagon-Like Peptide-1
GLP-1 RA	Glucagon-Like Peptide-1 Receptor Agonists
GMP	Good Manufacturing Practices
GSK	GlaxoSmithKline
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B Virus
HCV	Hepatitis C Virus
HER2	Human Epidermal Growth Factor Receptor 2
HICs	High-Income Countries
HIV	Human Immunodeficiency Virus
HR	Hormone Receptor
HTE	heavily treatment-experienced
HTE	Heavily treatment-experienced
ICI	Immune Checkpoint Inhibitors
IgG1	Immunoglobulin G1
IM	Intramuscular
INSTI	Integrase Strand Transfer Inhibitor
IP	Intellectual Property
ISL	Islatravir
IU	International Unit
IV	Intravenous
KRAS	Kirsten Rat Sarcoma Virus
LA	Long-Acting
LAI	Long-Acting Injectable
LEN	Lenacapavir

LGG	Low-Grade Glioma
LICs	Low-Income Countries
LMICs	Low- and Middle-Income Countries
LRTI	Lower Respiratory Tract Infections
LTBI	Latent Tuberculosis Infection
mAbs	Monoclonal Antibodies
MACE	Major Adverse Cardiovascular Events
MACE	Major Adverse Cardiovascular Events
MAGHP	Marketing Authorisation for Global Health Products
MASH	Metabolic dysfunction-Associated SteatoHepatitis
MATRIX	A USAID Project to Advance the Research and Development of Innovative HIV Prevention
MDR-RRTB	multidrug-resistant or rifampicin resistant tuberculosis
MDR-TB	Multi-Drug-Resistant Tuberculosis
MEK	Mitogen-Activated Protein Kinase Kinase
mg	Milligram
MPP	Medicines Patent Pool
MSD	Merck Sharp & Dohme
NCD	Non-Communicable Diseases
NNRTI	Non-Nucleoside Reverse Transcriptase Inhibitor
NRTTI	Nucleoside reverse transcriptase translocation inhibitor
NSCLC	Non Small Cell Lung Cancer
NSCLC	Non-Small Cell Lung Cancer
OEB	Occupational Exposure Bands
OEL	Occupational Exposure Limits
PADO	Paediatric Antiretroviral Drug Optimization
PAN-TB	Project to Accelerate New Treatments for Tuberculosis
pan-TB	Project aimed to research a pan-TB treatment regimen
Para III	Paragraph III Certification



PCR	Polymerase Chain Reaction
PD	Pharmacodynamics
PD-1	Programmed Cell Death 1
PD-L1	Programmed Cell Death Ligand 1
PD-L2	Programmed Cell Death Ligand 2
PFS	Pre-Filled Syringe
PK	Pharmacokinetics
PK/PD	Pharmacokinetics/Pharmacodynamics
PLHIV	People Living with HIV
PNP	Post-Natal Prophylaxis
PPR	pandemic preparedness and response
PrEP	Pre-Exposure Prophylaxis
PWID	People Who Inject Drugs
Q	Quarter
Q4M	Every 4 Months
QT	a measure of heart's electrical activity
R&D	Research and Development
RA	Receptor Agonist
RNA	Ribonucleic Acid
RPV	Rilpivirine
RR-TB	Rifampicin-Resistant Tuberculosis
RSV	Respiratory Syncytial Virus
SAGE	The WHO Strategic Advisory Group of Experts on Immunization
SAGE	Strategic Advisory Group of Experts on Immunization
SAP	Scientific Advisory Panel
SCLC	Small Cell Lung Cancer
SGLT2i	Sodium-Glucose Transport Protein 2 inhibitors
SNAC	Sodium N-(8-[2-hydroxy]benzoyl] amino) caprylate
SoC	Standard of Care

SOF	Sofosbuvir
SQ	Subcutaneous
SRA	Stringent Regulatory Authorities
STI	Sexually Transmitted Infections
SVR12	Sustained Virologic Response at 12 weeks
Swissmedic	Swissmedic Procedure for Scientific Advice and MAGHP
T1DM	Type 1 Diabetes Mellitus
T2D	Type 2 Diabetes Mellitus
T2DM	Type 2 Diabetes Mellitus
TAF	Tenofovir Alafenamide
TB	Tuberculosis
TDF	Tenofovir Disoproxil Fumarate
TDF	Tenofovir Disoproxil Fumarate
TKI	Tyrosine Kinase Inhibitor
TLD	Tenofovir/Lamivudine/Dolutegravir
TLD	Tenofovir/Lamivudine/Dolutegravir
TPT	Tuberculosis Preventive Therapy
UMICs	Upper-Middle-Income Countries
USAID	United States Agency for International Development
USFDA	The United States Food and Drug Administration
WHO	World Health Organization
WHO-PQ	WHO Pre-Qualification of Medicines Programme